Recent developments include the release of Q3 2026 financial results showing a net loss but revenue exceeding prior guidance, raising full year revenue guidance, and expanding multiomics capabilities through acquisitions and collaborations.

• 10x Genomics reported Q3 2026 financial results with a net loss but revenue exceeding prior guidance and raised full year revenue guidance [N1].
• The company held a Q3 2026 earnings call discussing key metrics and business trends [N2].
• Analysis of Q3 2026 earnings highlighted revenue growth and operational developments [N3].
• 10x Genomics expanded multiomics capabilities through acquisitions including Proteintech Genomics, Inc. [N1].
• The company collaborates with research institutions such as Fred Hutch and Cleveland Clinic on cancer biomarker and diagnostic research [N1].

The company’s recent acquisitions and partnerships enhance its technological capabilities and market reach in multiomics and cancer biomarker research. Its strong liquidity position supports ongoing investments in innovation and expansion. Raised full year revenue guidance and revenue exceeding prior expectations in Q3 2026 indicate operational momentum. Continued collaboration with leading research institutions may drive adoption of its technologies.

The company reported a net loss in Q3 2026 and negative EPS, reflecting ongoing profitability challenges. The genomics market is competitive and subject to rapid technological change, which may pressure margins and market share. Dependence on successful integration of acquisitions and collaborations introduces execution risks. Regulatory and reimbursement environments for diagnostic applications may pose uncertainties.

10x Genomics’ moat is supported by its proprietary technology platforms in genomic analysis, its expanding multiomics capabilities through strategic acquisitions, and collaborations with prominent research institutions. The company’s integrated product and service offerings, combined with licensing and royalty streams, create multiple revenue channels. Its strong liquidity and investment in technology development provide a foundation for sustaining competitive advantages in the genomics market.

• Profitability Risk: The company reported net losses and negative earnings per share in recent quarters, indicating ongoing challenges in achieving profitability.
• Market Competition and Technological Change: Rapid innovation and competition in the genomics and biotechnology sectors may impact the company’s market position and require continuous investment.
• Acquisition and Integration Risk: The success of recent acquisitions and collaborations depends on effective integration and realization of anticipated benefits.
• Regulatory and Reimbursement Uncertainty: Entering clinical and diagnostic markets involves regulatory approvals and reimbursement challenges that may affect commercialization.

• 10x Genomics, Inc. is a Delaware corporation with Class A and Class B common stock listed on Nasdaq under ticker TXG.
• The company files regular SEC reports including 10-K annual and 10-Q quarterly filings, with the latest 10-Q filed on 2026-11-05 covering the quarter ended 2026-09-30 [S2].
• As of September 30, 2026, 10x Genomics had cash and cash equivalents of $344.1 million (as of 2024-12-31) and current assets of $718.6 million, with current liabilities of $140.4 million, resulting in a current ratio of 5.12 and a cash ratio of 2.45 [S2].
• The company reported a net loss of $19.4 million for Q3 2026 and basic and diluted EPS of -$0.15 for the same period [S2].
• Revenue data is available historically, with $71.9 million reported for Q1 2020; more recent revenue figures are referenced in news but not detailed in SEC snapshot [S2].
• 10x Genomics reported Q3 2026 financial results publicly, including a loss but revenue exceeding prior guidance, and raised full year revenue guidance as of November 6, 2026 [N1].
• The company has engaged in acquisitions such as Scale Biosciences, Inc. and Proteintech Genomics, Inc., expanding its multiomics capabilities [S1][N1].
• 10x Genomics collaborates with research institutions such as Fred Hutch and Cleveland Clinic on cancer biomarker and diagnostics research [N1].
• The company’s business model includes product and service revenue streams, licensing and royalty revenue, and investments in technology and acquisitions to expand capabilities [S1][S2].
• Recent earnings calls and transcripts provide detailed discussion of key metrics and business trends [N2][N3][N4].
• The company maintains a strong liquidity position with significant cash and current assets relative to liabilities [S2].